Takeda Pharmaceutical Co Ltd (TAK)
13.62
+0.06
(+0.41%)
USD |
NYSE |
Nov 15, 16:00
13.62
0.00 (0.00%)
After-Hours: 20:00
Takeda Pharmaceutical Net Income (Quarterly): 619.69M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 619.69M |
| June 30, 2024 | 611.00M |
| March 31, 2024 | -20.33M |
| December 31, 2023 | 716.00M |
| September 30, 2023 | -332.51M |
| June 30, 2023 | 651.48M |
| March 31, 2023 | 235.71M |
| December 31, 2022 | 844.99M |
| September 30, 2022 | 446.94M |
| June 30, 2022 | 810.45M |
| March 31, 2022 | -97.77M |
| December 31, 2021 | 508.19M |
| September 30, 2021 | 417.60M |
| June 30, 2021 | 1.258B |
| March 31, 2021 | 1.861B |
| December 31, 2020 | 884.32M |
| September 30, 2020 | 38.04M |
| June 30, 2020 | 766.76M |
| March 31, 2020 | 15.83M |
| December 31, 2019 | -296.32M |
| September 30, 2019 | 631.45M |
| June 30, 2019 | 63.77M |
| March 31, 2019 | -265.54M |
| December 31, 2018 | 334.98M |
| September 30, 2018 | 434.46M |
| Date | Value |
|---|---|
| June 30, 2018 | 717.36M |
| March 31, 2018 | -498.34M |
| December 31, 2017 | 602.88M |
| September 30, 2017 | 252.69M |
| June 30, 2017 | 1.303B |
| March 31, 2017 | -446.18M |
| December 31, 2016 | 379.13M |
| September 30, 2016 | 242.03M |
| June 30, 2016 | 921.53M |
| March 31, 2016 | -290.57M |
| December 31, 2015 | 487.84M |
| September 30, 2015 | 243.92M |
| June 30, 2015 | 202.66M |
| March 31, 2015 | -1.893B |
| December 31, 2014 | 160.09M |
| September 30, 2014 | 269.75M |
| June 30, 2014 | 326.95M |
| March 31, 2014 | -258.81M |
| December 31, 2013 | 543.00M |
| September 30, 2013 | 432.93M |
| June 30, 2013 | 363.96M |
| March 31, 2013 | 105.01M |
| December 31, 2012 | 235.50M |
| September 30, 2012 | 409.84M |
| June 30, 2012 | 1.092B |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-332.51M
Minimum
Sep 2023
1.861B
Maximum
Mar 2021
496.95M
Average
559.59M
Median
Net Income (Quarterly) Benchmarks
| HUTCHMED (China) Ltd | -- |
| Astellas Pharma Inc | 241.22M |
| Nxera Pharma Co Ltd | 8.079M |
| PeptiDream Inc | 120.39M |
| Healios KK | -3.426M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 7.918B |
| Total Expenses (Quarterly) | 6.075B |
| EPS Diluted (Quarterly) | 0.1924 |
| Enterprise Value | 72.05B |
| Gross Profit Margin (Quarterly) | 66.47% |
| Profit Margin (Quarterly) | 7.83% |
| Earnings Yield | 4.44% |
| Operating Earnings Yield | 7.23% |
| Normalized Earnings Yield | 4.436 |